Concepedia

Publication | Open Access

Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033

DOIFull Paper Access

121

Citations

7

References

2014

Year

Jonathan Q. Tran, Jitesh Rana, Frederik Barkhof, Isaac Melamed, Hakop Gevorkyan, Mike P. Wattjes, Remko de Jong, Kristin Brosofsky, Soma Ray, Lei Xu,
Neurology Neuroimmunology & Neuroinflammation

Abstract

This study provides Class I evidence that BIIB033 is well tolerated and safe (serious adverse event rate 0%, 95% confidence interval 0-7.6%).

References

YearCitations

Page 1